Information  X 
Enter a valid email address

Creightons PLC (CRL)

  Print      Mail a friend       Annual reports

Monday 01 April, 2019

Creightons PLC

Issue of Equity and TVR

RNS Number : 7429U
Creightons PLC
01 April 2019
 

 

FOR IMMEDIATE RELEASE                                                                            1 April 2019

 

CREIGHTONS PLC ("Creightons" or "the Company")

Issue of Equity

Total Voting Rights

The Company today announces that it has issued from its block listing authority of 20 March 2019 in respect of employee share options 124,000 new Ordinary Shares of 1p each at a price of 4.50 pence per share; these shares rank pari passu with the existing Ordinary Shares in issue. 

Following this issue, the Company has the ability to issue a further 2,551,100 Ordinary Shares under its block listing facility. 

As a result of this issue, the total number of ordinary shares in issue now stands at 62,546,143 and the total number of voting rights in the Company is 62,546,143.

The above figure of 62,546,143 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation No. 596/2014 on market abuse.  Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Enquiries - Analysts and Investors

Nicholas O'Shea, Director, Creightons Plc                                                         01733 281000

Roland Cornish / Felicity Geidt, Beaumont Cornish Limited                           0207 628 3396

Authorised for release

 

Nicholas O'Shea, Director, Creightons plc

1 April 2019


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEUGUUACUPBGAG

a d v e r t i s e m e n t